Stockscreener 앱 받기
7.61
2.70%
0.20
시간 외 거래:
7.60
-0.01
-0.13%
전일 마감가:
$7.41
열려 있는:
$7.44
하루 거래량:
1.27M
Relative Volume:
0.80
시가총액:
$644.29M
수익:
$20.65M
순이익/손실:
$-192.65M
주가수익비율:
-2.9382
EPS:
-2.59
순현금흐름:
$-134.39M
1주 성능:
-3.79%
1개월 성능:
+34.93%
6개월 성능:
+8.71%
1년 성능:
-29.67%
1일 변동 폭
$7.38
$7.90
1주일 범위
$6.995
$8.05
52주 변동 폭
$4.305
$19.34
Verve Therapeutics Inc Stock (VERV) Company Profile
명칭
Verve Therapeutics Inc
전화
(978) 501-3026
주소
201 BROOKLINE AVENUE, BOSTON
VERV을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
VERV
Verve Therapeutics Inc
|
7.61 | 644.29M | 20.65M | -192.65M | -134.39M | -2.59 |
|
VRTX
Vertex Pharmaceuticals Inc
|
461.68 | 118.90B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
672.98 | 73.95B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
655.13 | 39.81B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
271.31 | 34.99B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
123.77 | 29.67B | 3.30B | -501.07M | 1.03B | -2.1146 |
Verve Therapeutics Inc Stock (VERV) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-04-08 | 개시 | H.C. Wainwright | Buy |
| 2023-04-13 | 개시 | Canaccord Genuity | Buy |
| 2023-02-01 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-12-15 | 개시 | Goldman | Sell |
| 2022-10-06 | 개시 | Credit Suisse | Neutral |
| 2022-08-25 | 업그레이드 | Stifel | Hold → Buy |
| 2022-06-17 | 개시 | BMO Capital Markets | Outperform |
| 2022-02-18 | 개시 | RBC Capital Mkts | Outperform |
| 2021-09-24 | 개시 | Stifel | Hold |
| 2021-07-12 | 개시 | Guggenheim | Buy |
| 2021-07-12 | 개시 | JP Morgan | Neutral |
| 2021-07-12 | 개시 | Jefferies | Buy |
| 2021-07-12 | 개시 | William Blair | Outperform |
모두보기
Verve Therapeutics Inc 주식(VERV)의 최신 뉴스
(VERV) Proactive Strategies - Stock Traders Daily
Millennium Management LLC Reduces Stake in Verve Therapeutics Inc - GuruFocus.com
Kuehn Law Encourages Investors of Verve Therapeutics, Inc. to Contact Law Firm - PR Newswire
Verve Therapeutics (NASDAQ:VERV) Trading Down 8.2%What's Next? - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Trading Up 5.6%Should You Buy? - MarketBeat
Nisa Investment Advisors LLC Has $241,000 Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Nisa Investment Advisors LLC - Defense World
Verve Therapeutics to Participate in the Guggenheim Securities SMID Cap Biotech Conference - GlobeNewswire
Inside Verve's Next Move: CEO Kathiresan Takes Center Stage at Elite Biotech Summit - StockTitan
Companies Like Verve Therapeutics (NASDAQ:VERV) Are In A Position To Invest In Growth - Yahoo Finance
2025-01-26 | Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Shareholders to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading Up 6.1%Should You Buy? - MarketBeat
Pixalate Releases Q4 2024 North America SSP Market Share Rankings for Connected TV (CTV), Mobile Apps, & Web: Verve No. 1 for Apple App Store Apps in US (44%), Index Exchange No. 1 on Web in US (9%), & Sonobi Leads in Canada on Roku (33%) - GlobeNewswire Inc.
Verve Therapeutics (VERV) Moves 18.7% Higher: Will This Strength Last? - Yahoo Finance
Brokers Offer Predictions for VERV FY2025 Earnings - MarketBeat
Verve Therapeutics (NASDAQ:VERV) Stock Price Up 6.1%Here's Why - MarketBeat
Cantor Fitzgerald Forecasts VERV FY2025 Earnings - MarketBeat
(VERV) Trading Advice - Stock Traders Daily
2025-01-19 | Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Shareholders to Inquire about Securities Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics (NASDAQ:VERV) Trading 8.6% HigherTime to Buy? - MarketBeat
GAMMA Investing LLC Has $34,000 Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
JPMorgan Chase & Co. Decreases Stock Holdings in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Harbor Capital Advisors Inc. Sells 11,980 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Verve Therapeutics, Inc. (NASDAQ:VERV) Stake Raised by Barclays PLC - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Shares Purchased by Barclays PLC - Defense World
Analysts’ Revisions Show Improving Sentiment For Verve Therapeutics Inc (NASDAQ: VERV) - Stocks Register
Verve Therapeutics Announces Pipeline Progress and Anticipated 2025 Milestones - The Manila Times
Bronstein, Gewirtz & Grossman, LLC Encourages Verve Therapeutics, Inc. (VERV) Stockholders to Inquire about Securities Investigation - AccessWire
Learn to Evaluate (VERV) using the Charts - Stock Traders Daily
Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Verve Therapeutics, Inc. (VERV) and Encourages Investors to Learn More About the Investigation - AccessWire
Verve Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Verve Therapeutics CEO to Present at J.P. Morgan Healthcare Conference 2025 - StockTitan
Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - AccessWire
2025-01-05 | Verve Therapeutics, Inc. (VERV) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation | NDAQ:VERV | Press Release - Stockhouse Publishing
Verve Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - The Manila Times
Verve Therapeutics Grants New Employee RSU Awards Under 2024 Inducement Plan - StockTitan
Verve Therapeutics (NASDAQ:VERV) Trading 6.2% HigherWhat's Next? - MarketBeat
Franklin Resources Inc. Buys 5,914 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect - AccessWire
Geode Capital Management LLC Raises Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
2025-01-02 | Bronstein, Gewirtz & Grossman, LLC Is Investigating Verve Therapeutics, Inc. (VERV) And Encourages Investors to Connect | NDAQ:VERV | Press Release - Stockhouse Publishing
Barclays PLC Grows Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Barclays PLC Purchases 129,944 Shares of Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? - Insider Monkey
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Verve Therapeutics (NASDAQ:VERV) Trading Down 5.9%What's Next? - MarketBeat
Verve Therapeutics, Inc. (NASDAQ:VERV) Holdings Raised by Stifel Financial Corp - Defense World
State Street Corp Boosts Stock Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - Defense World
State Street Corp Has $20.59 Million Position in Verve Therapeutics, Inc. (NASDAQ:VERV) - MarketBeat
Verve Therapeutics Inc (VERV) 재무 분석
매출
순이익
현금흐름
주당 순 이익
3.95%
2.39%
자본화:
|
볼륨(24시간):